1,2,3,4,5-pentafluoro-6-neopentylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,2,3,4,5-pentafluoro-6-neopentylbenzene
• 英文别名: 1-(2,2-Dimethylpropyl)-2,3,4,5,6-pentafluorobenzene
• 化学式: C₁₁H₁₁F₅
• 分子量: 238.2
• InChiKey: WOXVXCSDNAMTRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,3-二甲基-1-丁酸 在 4-二甲氨基吡啶 、 2,4,5,6-四(9H-咔唑-9-基)异酞腈 、 copper(II) bis(trifluoromethanesulfonate) 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 20.0h， 生成 1,2,3,4,5-pentafluoro-6-neopentylbenzene
  参考文献：
  名称：

  脂肪族 N-羟基邻苯二甲酰亚胺酯与多氟芳基亲核试剂的光催化脱羧偶联

  摘要：

  多氟芳烃是医学和材料化学中的一类重要化合物。烷基化多氟芳烃的合成仍然具有挑战性。在这里，我们描述了脂肪族羧酸的 N-羟基邻苯二甲酰亚胺酯与多氟芳基锌试剂 (Zn-Ar F ) 通过协同光氧化还原和铜催化进行的脱羧偶联反应。该方法很容易将伯烷基羧酸和仲烷基羧酸转化为相应的多氟芳基化合物，该化合物可以具有广泛的 F 含量 (2F-5F) 和芳基上可变的 F 取代模式。实现了广泛的范围和良好的官能团相容性，包括在天然产物和药物衍生的底物上。机理研究表明，[Cu-(Ar F ) 2 ]物种可能负责将多氟芳基转移至烷基自由基。

  DOI：

  10.1002/anie.202108465

文献信息

• Macrocyclic Modulators of the Ghrelin Receptor
  申请人：Ocera Therapeutics, Inc.

  公开号：US20180110824A1

  公开（公告）日：2018-04-26

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新颖的构象定义明确的大环化合物，已经证明是生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、遗传疾病、过度增殖性疾病和炎症性疾病。
• Luciferin Derivatives from Bicyclic Reactants and Aminothiol Derivatives and Methods of Use Thereof
  申请人：The Regents of the University of California

  公开号：US20130287699A1

  公开（公告）日：2013-10-31

  The present disclosure features a condensation reaction and a luciferin-unmasking reaction that can be carried out under physiological conditions. In general, the condensation reaction involves reacting a bicyclic reactant with an aminothiol derivative, generating a luciferin or luciferin derivative. A luciferin can provide detectable luminescence. A luciferin derivative can be unmasked to provide detectable luminescence in a luciferin-unmasking reaction. The present disclosure provides bicyclic reactants and aminothiol derivatives suitable for use in the condensation reaction. The condensation and luciferin-unmasking reactions find use in a variety of applications, which are also provided.

  本公开涉及一种可以在生理条件下进行的缩合反应和发光素暴露反应。通常，缩合反应涉及将双环反应物与氨基硫醇衍生物反应，生成发光素或发光素衍生物。发光素可以提供可检测的发光。发光素衍生物可以在发光素暴露反应中被揭示出来，提供可检测的发光。本公开提供适用于缩合反应的双环反应物和氨基硫醇衍生物。缩合和发光素暴露反应在各种应用中有用，这些应用也被提供。
• HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Natarajan Iyer Sesha

  公开号：US20070287670A1

  公开（公告）日：2007-12-13

  The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.

  本发明提供了新型的人类胰高血糖素样肽-1 (GLP-1) 肽类模拟物，这些模拟物模仿了天然的 GLP-1 肽的生物活性，因此可用于治疗或预防与 GLP 活性相关的疾病或疾病。此外，本发明提供了新型的化学修饰肽，这些肽不仅可以刺激 II 型糖尿病患者的胰岛素分泌，还可以产生其他有益的胰岛素促进反应。这些合成的 GLP-1 模拟物肽类表现出对蛋白酶水解的稳定性增加，使它们成为口服或静脉注射治疗的理想候选药物。
• Substituted imidazoles as bombesin receptor subtype-3 modulators
  申请人：Dobbelaar Peter H.

  公开号：US20100204236A1

  公开（公告）日：2010-08-12

  Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

  某些新型取代咪唑是人类炸弹肽受体的配体，特别是人类炸弹肽受体亚型-3（BRS-3）的选择性配体。因此，它们可用于治疗、控制或预防对BRS-3调节敏感的疾病和障碍，例如肥胖症和糖尿病。
• SUBSTITUTED BENZOCHALCOGENOACENE COMPOUND, THIN FILM COMPRISING THE COMPOUND, AND ORGANIC SEMICONDUCTOR DEVICE INCLUDING THE THIN FILM
  申请人：Miyata Yasuo

  公开号：US20120190868A1

  公开（公告）日：2012-07-26

  Provided are a novel compound suitable as an organic semiconductor material, the compound being a substituted benzochalcogenoacene compound represented by the formula (1), a thin film comprising the compound, and an organic semiconductor device having the thin film as a component. In the formula (1), each E independently represents a sulfur or selenium atom, and R 1 and R 2 each independently represents a hydrogen atom, an optionally substituted C 4-30 alkyl group, an optionally substituted C 4-30 alkoxy group, an optionally substituted C 6-30 aryl group, an optionally substituted C 7-30 aralkyl group, an optionally substituted C 4-30 heteroaryl group, an optionally substituted C 5-30 heteroaralkyl group, or an optionally fluorinated C 3-30 trialkylsilyl group, both R 1 and R 2 being not hydrogen atoms.

  提供了一种新型化合物，适用于有机半导体材料，该化合物是由式（1）表示的取代苯基硫属或硒属芴化合物，还包括该化合物的薄膜以及将该薄膜作为组件的有机半导体器件。在式（1）中，每个E分别表示硫或硒原子，R1和R2各自独立地表示氢原子、可选取代的C4-30烷基、可选取代的C4-30烷氧基、可选取代的C6-30芳基、可选取代的C7-30芳基烷基、可选取代的C4-30杂环芳基、可选取代的C5-30杂环芳基烷基或可选氟化的C3-30三取代硅烷基，R1和R2均不是氢原子。